Takeda Pharmaceutical Company Limited
[Takeda Pharmaceutical] Q1 FY2026 Financial Results | Revenue of ¥1.2199 trillion (YoY +10.2%)
Takeda Pharmaceutical's Q1 FY2026 financial results show revenue of ¥1.2199 trillion (YoY +10.2%) and operating profit of ¥201.4 billion (△3.1%), with net income of ¥113.3 billion (△8.9%). Attention is needed on future performance trends.
Key Figures
- Revenue: ¥1.2199 trillion (YoY +10.2%)
- Operating Profit: ¥201.4 billion (△3.1%)
- Net Income: ¥113.3 billion (△8.9%)
AI要約
Performance Overview
Takeda Pharmaceutical's Q1 FY2026 showed strong revenue of ¥1.2199 trillion (+10.2%), while operating profit and net income declined compared to the same period last year. Revenue growth was driven by exchange rate factors and contributions from new products, with sales expansion in key segments such as gastrointestinal disorders and oncology. Core indicators remained solid, but increased R&D and SG&A expenses put pressure on profits.
Outlook and Impact on Shareholders
The full-year forecast for FY2026 projects revenue of ¥4.64 trillion (+3%), but profits face continued challenges from rising costs and R&D investments. The dividend forecast remains at ¥102, with ongoing shareholder returns. The company’s strategy emphasizes new drug development and overseas expansion to achieve long-term growth. Investors should monitor exchange rate fluctuations and the progress of new drug launches.
Takeda Pharmaceutical Company Limited
Company overview · Stock price · Financial data · All IR
